Study to Understand Molecular, Immune, and Metabolic Mechanisms in Glioblastoma Progression and Recurrence to Find New Treatments

What this Trial Is About

Glioblastoma is the most common and aggressive primary brain tumor in adults, with relapse occurring almost always despite standard treatments like surgery, radiation, and chemotherapy. This study aims to better understand the molecular, immune, and metabolic processes involved in glioblastoma progression and recurrence by analyzing blood and tumor samples from patients undergoing surgery for newly diagnosed or recurrent glioblastoma. Researchers hope to identify new therapeutic targets and improve current treatment strategies. Participants will provide a 50 ml blood sample before surgery and two small tumor samples during surgical tumor removal. These samples will be analyzed using advanced techniques such as transcriptomic and metabolomic analysis, including spatial transcriptomics and metabolomics. The study also involves creating preclinical models like patient-derived xenografts and generating specialized immune cells to explore new drug therapies with radiosensitizing effects and gamma-delta T cell immunotherapy. Throughout the study, participants will be involved during their surgical procedure and sample collection. Researchers will evaluate molecular, metabolic, and immune mechanisms at the time of inclusion. The study involves detailed biological analysis but does not involve additional treatments beyond surgery. Participation covers sample collection and data analysis, with monitoring focusing on understanding glioblastoma biology to guide future therapies. The study is planned to continue until October 2031.

A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression